ChromaDex Initiates Second Human Clinical Study for its Caffeine Ingredient, PURENERGY

14 May 2014 --- ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced the initiation of the second human clinical study for PURENERGY, its patented caffeine ingredient.

The Institutional Review Board (IRB)-approved, crossover design study will be administered by Medicus Research and will build on the results from the first PURENERGY human study, which was performed in the summer of 2013. The new clinical trial will study the bioavailability and pharmacokinetics of PURENERGY as compared to caffeine and pTeroPure pterostilbene alone at repeated doses.

PURENERGY is an innovative patented caffeine ingredient that is a cocrystal combination of caffeine and ChromaDex's patented pTeroPure pterostilbene. The combination forms a unique crystalline structure that has superior benefits as compared to caffeine alone. Recently, caffeinated energy products have come under increased regulatory and political scrutiny because of the possible risks associated with consuming high amounts of caffeine. PURENERGY offers product formulators a unique solution to reduce total caffeine content while optimizing the consumer experience – as well as delivering the benefits of pTeroPure.

Frank L. Jaksch Jr., CEO of ChromaDex, commented, "This study will provide additional valuable insight into the benefits of PURENERGY, building on our previous successful human study. We have already had tremendous interest in PURENERGY and anticipate seeing numerous retail products launched in 2014 and beyond that incorporate PURENERGY as a compelling alternative ingredient to caffeine alone."

Results from the first study conducted in 2013 showed that PURENERGY delivers 30 percent more caffeine to the bloodstream and also extends the half-life of caffeine by 25 percent as compared to caffeine alone. The study results suggest:

- Formulators of energy products have the ability to reduce the total amount of caffeine in their products without sacrificing consumers' expectations from such products.
- A rapid and sustained energy boost for at least six hours.

In addition to serving as a caffeine alternative, PURENERGY has additional health benefits stemming from its cocrystal formulation with ChromaDex's patented pTeroPure pterostilbene, which has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic functions. The findings from the first clinical trial of the pure compound, which were presented in September 2012 at the American Heart Association's High Blood Pressure Research 2012 Scientific Sessions, showed that pTeroPure (pterostilbene) significantly reduced blood pressure in adults. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.